drugset / Trial / NCT04106297

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970

NCT04106297

Phase 1 Completed 100 enrolled Lakefront Biotherapeutics NV
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of GLPG3970 in healthy volunteers after single oral administrations of GLPG3970 (SAD), compared to placebo (part 1 and 1bis) and after multiple (for 14 days) oral administrations of GLPG3970 (MAD), compared to placebo (part 2). The effect of food (FE) (high-fat, high calorie) on the pharmacokinetics of GLPG3970 and the relative bioavailability (rBA) of an oral solution versus a solid formulation will be assessed (part 3 and 3bis). Part 4 of the study is to evaluate the safety and tolerability of GLPG3970 in subjects with moderate to severe psoriasis when administered daily for 6 weeks.

Timeline

Start
2019-09-10
Primary completion
2021-03-05
Completion
2021-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG3970 Unknown Oral

Indications